Updates
HealthLeaders: Allegheny Health Network benefits from new rapid test

Feb 10, 2020 — From HealthLeaders: For the past eight months, the team at Allegheny Health Network has been using the Accelerate Pheno test system to analyze bloodstream infections and determine the best antibiotic therapy for sepsis patients. Sepsis is the body’s extreme reaction to an infection, which can result in life-threatening symptoms such as multiple organ failure. Annually, […]

Continue reading


Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results

Jan 13, 2020 — TUCSON, Ariz., Jan. 13, 2020 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter and year ending December 31, 2019. Highlights for the fourth quarter and full-year 2019 are presented below. 2019 Fourth Quarter and Full-Year Financial Highlights Commercially contracted instruments were 137 in the fourth quarter and 304 […]

Continue reading


Studies Confirm Rapid Phenotypic Susceptibility Results Enable Earlier Antimicrobial Intervention and Better Patient Outcomes

Oct 03, 2019 — From IDWeek™, the annual meeting of the Infectious Diseases Society of America (IDSA) held in Washington, DC October 2 – 6. TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that […]

Continue reading


Clinical Endpoints Achieved Across Mayo Clinic/UCLA, University of Iowa, and UAMS Studies

Sep 18, 2019 — Accelerate Diagnostics, Inc. recently highlighted the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019.   “We are thrilled with the results of these clinical studies, which provide further evidence of the clinical value of Pheno,” commented Dr. Romney Humphries, Chief Scientific Officer of […]

Continue reading


See all news

See the Latest data from IDWeek™

See the Latest data from ASM


Media kit

Media contact

Andy Chasteen
520.365.3100
achasteen@axdx.com


Company information

About the company
Bios
Our products


Digital assets

Enter your email address below for access to photos, logos and videos.

See Terms and Use Policy


Connect with us

  Like us on Facebook
  Follow us on Twitter
  See us on Linkedin
  Visit us on Google+

Upcoming Events
MEDLAB ME 2020

February 3-6, 2020
Dubai World Trade Centre, UAE

Learn more

Want to hear when we announce our next event?

Stay up to date with Accelerate by joining our mailing list.

Sign up today
Past Events
RICAI 2019

December 16-17, 2019
Palais des Congrès de Paris, France

Learn more

DIVI 19

December 4-6 2019
Hamburg Messe, Germany

Learn more

FIS 2019

November 11-14, 2019
Edinburgh, Scotland

Learn more

AMCLI 2019

November 9-12, 2019
Palacongressi Di Rimini, IT

Learn more

IDWeek 2019

October 2-6, 2019
Washington, DC

Learn more

ASM Microbe 2019

June 20–24, 2019
San Francisco

Learn more

Over the past several years, Accelerate Diagnostics, together with our scientific collaborators, conducted numerous scientific studies supporting the exciting capabilities of our ID/AST System. Many of these studies resulted in posters presented at international conferences and peer-reviewed publications. We have conducted over 87,000 internal identification and susceptibility experiments across a panel of more than 20 of the most clinically prevalent species in sample types such as positive blood cultures and BALs. These studies demonstrated compelling performance versus reference and comparator methods, the results of which have been consistently duplicated by our clinical research partners. Below you will find links to some of these posters and publications.


These publications may include information from one or more organism/antimicrobial combinations that are research use only and not for use in diagnostic procedures.

Certain uses of devices included in these publications may not have been approved or cleared by the U.S. Food and Drug Administration or other regulatory bodies.

See product labeling for instructions for use, warnings, and limitations specific to each product and region.

Okay, I understand. Show me the publications.